Ayahuasca
Small molecule
Ayahuasca is one of 52 small molecule programs targeting Treatment Resistant Depression. It is currently in development.
1
Indications
5
Total Trials
3
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Treatment Resistant Depression
#DrugCompanyPhaseTrials
1Spravato
WWim Janssens
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Bayer Aspirin
BayerApproved
Abilify
OtsukaApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Mirapex
Boehringer IngelheimApproved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Esketamine3 trials
Treatment Resistant Depression1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ayahuasca. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- UUniversity of Sao Paulo